Usted buscó: data cutoff (Inglés - Maltés)

data cutoff: 07 sep 2012
data sa meta nġabret id-dejta: 07 ta’ settembru, 2012

data
dejta

2007 data
dejta tal-2007

mic-data
tagħrif-mic

clinical data
dejta klinika

data protection,
protezzjoni tad-dejta,

cutoff: 07 sep 2012
data sa meta nġabret id-dejta: 07 ta’ settembru, 2012

database cutoff date 06 january 2014
data ta’ riferiment għad-database 06 ta’ jannar 2014

overall survival data were not mature at the time of data cutoff.
id-dejta ta’ sopravivenza globali ma kinitx matura fiż-żmien tal-għeluq tad-dejta.

at clinical cutoff, 1337 deaths were reported.
meta waqfet tinġabar id-data klinika, kienu rrappurtati 1337 mewt.

per data cutoff dates 01 june 2011 (study 1001) and 15 february 2012 (study 1005).
skont id-dati tal-għeluq għad-dejta: 1 ta’ Ġunju 2011 (studju 1001) u 15 ta’ frar 2012 (studju 1005).

the median pfs at the time of data cutoff was 19.3 months (95% ci: 14.8, nr).
il-pfs medjan fiż-żmien tal-għeluq tad-dejta kien ta’ 19.3 xhur (95% ci: 14.8, nr).

a total of 934 patients with alk-positive advanced nsclc were treated with crizotinib in study 1005 at the time of data cutoff for pfs and orr analysis.
total ta’ 934 pazjent b’nsclc avvanzat pożittiv għall-alk ingħataw trattament bi crizotinib fl- istudju 1005 fiż-żmien ta’ meta ttieħdet l-aħħar dejta għall-analiżi ta’ pfs u orr.

pfs data from study 1005 included 807 patients in the safety analysis population who were identified by the fish assay (data cutoff date 15 february 2012).
id-dejta dwar il-pfs u l-os mill-istudju 1005 kienet tinkludi 807 pazjenti fil-popolazzjoni tal- analiżi dwar is-sigurtà li kienu identifikati bit-test ta’ fish (data tal-għeluq għad-dejta: 15 ta’ frar 2012).

no clear cutoff for pd-l1 expression can reliably be established when considering the relevant endpoints of tumour response and pfs.
l-ebda cut-off ċara għall-espressjoni ta’ pd-l1 ma tista’ tiġi stabbilita b’mod affidabbli meta jiġu kkunsidrati l-punti tat-tmiem rilevanti tar-rispons tat-tumur u l-pfs.

post-baseline ns5b sequences were available for 225 of the 226 subjects, with deep sequencing data (assay cutoff of 1%) from 221 of these subjects.
sekwenzi ns5b wara l-linja bażi kienu disponibbli għal 225 mill-226 individwu, b’dejta b’sekwenzar profond (cutoff tal-assaġġ ta’ 1%) ta’ 221 minn dawn l-individwi.

for the purpose of this table, a cutoff of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
għall-iskop ta’ din it-tabella, ġie użat livell minimu ta’ 5% biex jiġu inklużi dawk l-avvenimenti kollha li l-awtur ħaseb li setgħu kellhom relazzjoni ma’ pemetrexed.

figure 3: progression-free survival by pd-l1 expression: 5% cutoff (ca209067)
figura 3: sopravivenza mingħajr progessjoni mill-espressjoni ta’ pd-l1: cutoff ta’ 5% (ca209067)

a total of 149 alk-positive advanced nsclc patients, including 125 patients with previously treated alk-positive advanced nsclc, were enrolled into study 1001 at the time of data cutoff for pfs and orr analysis.
total ta’ 149 pazjent b’nsclc avvanzat pożittiv għall-alk, li jinkludu 125 pazjent b’nsclc avvanzat pożittiv għall-alk ittrattati minn qabel ġew irreġistrati fl-istudju 1001 fiż-żmien ta’ meta ttieħdet l-aħħar dejta għall-analiżi ta’ pfs u orr.

^ table 1 shows pooled data from the overall treatment period in cleopatra (data cutoff 11 february 2014; median number of cycles of perjeta was 24); and from the neoadjuvant treatment period in neosphere (median number of cycles of perjeta was 4, across all treatment arms) and tryphaena (median number of cycles of perjeta was 3 – 6 across treatment arms)
^ tabella 1 turi dejta miġbura mill-perjodu kollu tal-kura f’cleopatra (data meta waqfet tinġabar id-dejta 11 ta’ frar 2014; numru medjan ta’ ċikli ta’ perjeta kien ta’ 24); u mill-perjodu ta’ kura neoawżiljarja f’neosphere (numru medjan ta’ ċikli ta’ perjeta kien ta’ 4, tul il-gruppi ta’ kura kollha) u tryphaena (numru medjan ta’ ċikli ta’ perjeta kien ta’ 3 - 6 tul il-gruppi ta’ kura)